{"id":"NCT00847613","sponsor":"Pfizer","briefTitle":"A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","officialTitle":"Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2011-04","completion":"2012-02","firstPosted":"2009-02-19","resultsPosted":"2013-01-09","lastUpdate":"2024-05-16"},"enrollment":800,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":["Double-blind, placebo-controlled period"]},{"type":"DRUG","name":"CP-690,550","otherNames":["Double-blind, Active Extension Period"]},{"type":"DRUG","name":"CP-690,550","otherNames":["Double-blind, placebo-controlled period"]},{"type":"DRUG","name":"CP-690,550","otherNames":["Double-blind, Active Extension Period"]},{"type":"DRUG","name":"Placebo","otherNames":["Double-blind, placebo-controlled period"]},{"type":"DRUG","name":"CP-690,550","otherNames":["Double-blind, Active Extension Period"]},{"type":"DRUG","name":"Placebo","otherNames":["Double-blind, Active Extension Period"]},{"type":"DRUG","name":"CP-690,550","otherNames":["Double-blind, placebo-controlled period"]}],"arms":[{"label":"Sequence 1","type":"EXPERIMENTAL"},{"label":"Sequence 2","type":"EXPERIMENTAL"},{"label":"Sequence 3","type":"PLACEBO_COMPARATOR"},{"label":"Sequence 4","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.","primaryOutcome":{"measure":"Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6","timeFrame":"Month 6","effectByArm":[{"arm":"CP-690,550 5 mg","deltaMin":51.46,"sd":null},{"arm":"CP-690,550 10 mg","deltaMin":61.81,"sd":null},{"arm":"Placebo","deltaMin":25.32,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":115,"countries":["United States","Australia","Brazil","Bulgaria","Canada","Colombia","Czechia","Greece","India","Japan","Mexico","Poland","South Korea","Taiwan","Ukraine"]},"refs":{"pmids":["39192350","38958913","37925660","37453736","36931693","36814062","36601090","36600185","36526796","35577477","35382883","34921355","34870800","33127856","33059710","33057725","32816215","30666826","30177460","29949132","29761420","28143815","26275429","25047021","23348607"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921044&StudyName=A%202-Year%20Phase%203%20Study%20Of%20CP-690%2C550%20In%20Patients%20With%20Active%20Rheumatoid%20Arthritis%20On%20Background%20Methotrexate"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":321},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Bronchitis","Hypertension"]}}